Analyst Ratings For BHVN – Biohaven Pharmaceutical (NYSE:BHVN)
Today, BHVN – Biohaven Pharmaceutical (NYSE:BHVN) stock was downgraded by Barclays from Overweight to Equal Weight with a price target of $30.00.
Some recent analyst ratings include
- 4/5/2018-Barclays was Downgraded by analysts at Barclays from a “Overweight ” rating to a ” Equal Weight” rating. They now have a $30.00 price target on the stock.
- 3/26/2018-Piper Jaffray Reiterated Rating of Buy.
- 3/26/2018-Canaccord Genuity Reiterated Rating of Buy .
- 2/22/2018-Needham & Company LLC Reiterated Rating of Buy.
- 10/3/2017-William Blair Reiterated Rating of Outperform.
- 10/3/2017-Morgan Stanley Reiterated Rating of Overweight .
- On 3/12/2018 Robert Berman, Insider, sold 35,000 with an average share price of $30.11 per share and the total transaction amounting to $1,053,850.00.
- On 3/1/2018 Kimberly Gentile, VP, sold 5,000 with an average share price of $32.87 per share and the total transaction amounting to $164,350.00.
- On 2/21/2018 James Engelhart, CFO, sold 538 with an average share price of $29.60 per share and the total transaction amounting to $15,924.80.
- On 2/12/2018 Robert Berman, Insider, sold 35,000 with an average share price of $30.42 per share and the total transaction amounting to $1,064,700.00.
- On 2/1/2018 Kimberly Gentile, VP, sold 5,000 with an average share price of $32.78 per share and the total transaction amounting to $163,900.00.
- On 1/31/2018 Gregory Bailey, Director, sold 50,000 with an average share price of $33.71 per share and the total transaction amounting to $1,685,500.00.
- On 1/22/2018 Gregory Bailey, Director, sold 49,000 with an average share price of $30.76 per share and the total transaction amounting to $1,507,240.00.
Recent Trading Activity for BHVN – Biohaven Pharmaceutical (NYSE:BHVN)
Shares of BHVN – Biohaven Pharmaceutical closed the previous trading session at 24.32 down -0.82 3.26% with 56762 shares trading hands.